
EquitySector - HealthcareVery High Risk
Direct
NAV (09-Jul-26)
Returns (Since Inception)
Fund Size
₹1,308 Cr
Expense Ratio
1.21%
ISIN
INF789F01TO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+14.98%
+11.62% (Cat Avg.)
3 Years
+26.90%
+22.74% (Cat Avg.)
5 Years
+15.62%
+13.68% (Cat Avg.)
10 Years
+14.71%
+14.53% (Cat Avg.)
Since Inception
+16.45%
— (Cat Avg.)
| Equity | ₹1,243.18 Cr | 95.05% |
| Others | ₹64.81 Cr | 4.95% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹111.75 Cr | 8.54% |
| Ajanta Pharma Ltd | Equity | ₹66.41 Cr | 5.08% |
| Net Current Assets | Cash | ₹64.72 Cr | 4.95% |
| Divi's Laboratories Ltd | Equity | ₹62 Cr | 4.74% |
| Gland Pharma Ltd | Equity | ₹53.71 Cr | 4.11% |
| Caplin Point Laboratories Ltd | Equity | ₹52.52 Cr | 4.02% |
| Lupin Ltd | Equity | ₹49.31 Cr | 3.77% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹46.01 Cr | 3.52% |
| Alkem Laboratories Ltd | Equity | ₹41.12 Cr | 3.14% |
| Dr Reddy's Laboratories Ltd | Equity | ₹39.36 Cr | 3.01% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹38.96 Cr | 2.98% |
| Fortis Healthcare Ltd | Equity | ₹38.28 Cr | 2.93% |
| Ipca Laboratories Ltd | Equity | ₹35.73 Cr | 2.73% |
| Global Health Ltd | Equity | ₹34.16 Cr | 2.61% |
| Anthem Biosciences Ltd | Equity | ₹32.62 Cr | 2.49% |
| Cohance Lifesciences Ltd | Equity | ₹31.93 Cr | 2.44% |
| Procter & Gamble Health Ltd | Equity | ₹31.63 Cr | 2.42% |
| Viyash Scientific Ltd | Equity | ₹30.35 Cr | 2.32% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹28.56 Cr | 2.18% |
| Sai Life Sciences Ltd | Equity | ₹28.34 Cr | 2.17% |
| Marksans Pharma Ltd | Equity | ₹27.28 Cr | 2.09% |
| Rainbow Childrens Medicare Ltd | Equity | ₹26.91 Cr | 2.06% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹25.67 Cr | 1.96% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹25.45 Cr | 1.95% |
| Aurobindo Pharma Ltd | Equity | ₹25.26 Cr | 1.93% |
| Sudeep Pharma Ltd | Equity | ₹22.55 Cr | 1.72% |
| Cipla Ltd | Equity | ₹21.98 Cr | 1.68% |
| Metropolis Healthcare Ltd | Equity | ₹20.9 Cr | 1.60% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹19.35 Cr | 1.48% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹17.9 Cr | 1.37% |
| Dr. Lal PathLabs Ltd | Equity | ₹16.46 Cr | 1.26% |
| Alembic Pharmaceuticals Ltd | Equity | ₹16.45 Cr | 1.26% |
| Windlas Biotech Ltd | Equity | ₹16.02 Cr | 1.22% |
| Pfizer Ltd | Equity | ₹15.24 Cr | 1.17% |
| Laxmi Dental Ltd | Equity | ₹13.47 Cr | 1.03% |
| Emcure Pharmaceuticals Ltd | Equity | ₹12.72 Cr | 0.97% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹11.4 Cr | 0.87% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹11.11 Cr | 0.85% |
| Aarti Pharmalabs Ltd | Equity | ₹10.2 Cr | 0.78% |
| Orchid Pharma Ltd | Equity | ₹9.86 Cr | 0.75% |
| Jubilant Pharmova Ltd | Equity | ₹8.71 Cr | 0.67% |
| Biocon Ltd | Equity | ₹8.37 Cr | 0.64% |
| Syngene International Ltd | Equity | ₹7.17 Cr | 0.55% |
| Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.09 Cr | 0.01% |
Large Cap Stocks
18.48%
Mid Cap Stocks
32.83%
Small Cap Stocks
43.73%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,243.18 Cr | 95.05% |
Standard Deviation
This fund
16.35%
Cat. avg.
16.29%
Lower the better
Sharpe Ratio
This fund
1.16
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.71
Higher the better
Since May 2022
ISIN INF789F01TO9 | Expense Ratio 1.21% | Exit Load 1.00% | Fund Size ₹1,308 Cr | Age 13 years 6 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,62,105 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments